Cerebrolyisin

Phase 3Small molecule

YYonsei University

Cerebrolyisin is one of 7 small molecule programs targeting Aphasia. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AphasiaRecruiting

AphasiaPhase 3

Recruiting

Competition

Competitive Landscape

7 competitors in Aphasia

#DrugCompanyPhaseTrials

Namenda

AbbVie

Approved

2 2

Aricept

Eisai

Approved

2 3

Keppra

Lexapro

1 5

Cerebrolyisin

YYonsei University

Phase 3

1 6

Reminyl

WWim Janssens

Preclinical

1 7

Venlafaxine Hydrochloride

Teva

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Post-ApprovalRecruiting

Aphasia

NCT06897176

Clinical

Trials by Indication[1]

Aphasia1 trial

Effects of Cerebrolysin on Language Ability in Non-fluent Aphasia Patients After Stroke: A Randomized, Placebo-controlled, Double-blinded, Single Center Study

Recruiting·YYonsei University·Phase 4·NCT06897176·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Cerebrolyisin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Cerebrolyisin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Cerebrolyisin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Yonsei University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: YYonsei University

Cerebrolyisin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Aphasia1 trial

References

Drug Info

Quick Facts

Related News